These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
778 related articles for article (PubMed ID: 33169433)
1. Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder. Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR Int J Geriatr Psychiatry; 2021 May; 36(5):684-696. PubMed ID: 33169433 [TBL] [Abstract][Full Text] [Related]
2. Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study. Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR J Gen Intern Med; 2020 Jul; 35(7):2084-2093. PubMed ID: 32026255 [TBL] [Abstract][Full Text] [Related]
3. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR Curr Med Res Opin; 2021 Aug; 37(8):1303-1313. PubMed ID: 33890538 [TBL] [Abstract][Full Text] [Related]
4. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724 [TBL] [Abstract][Full Text] [Related]
5. Risk of delirium associated with antimuscarinics in older adults: A case-time-control study. Nishtala PS; Chyou TY Pharmacoepidemiol Drug Saf; 2022 Aug; 31(8):883-891. PubMed ID: 35587029 [TBL] [Abstract][Full Text] [Related]
6. Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study. Matta R; Gomes T; Juurlink D; Jarvi K; Herschorn S; Nam RK Eur Urol Focus; 2022 Sep; 8(5):1433-1440. PubMed ID: 34742663 [TBL] [Abstract][Full Text] [Related]
7. Risk of overactive bladder associated with cholinesterase inhibitors in dementia. Masurkar PP; Chatterjee S; Sherer JT; Chen H; Johnson ML; Aparasu RR J Am Geriatr Soc; 2022 Mar; 70(3):820-830. PubMed ID: 34854475 [TBL] [Abstract][Full Text] [Related]
8. Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study. Arana A; Margulis AV; McQuay LJ; Ziemiecki R; Bartsch JL; Rothman KJ; Franks B; D'Silva M; Appenteng K; Varas-Lorenzo C; Perez-Gutthann S Pharmacotherapy; 2018 Jun; 38(6):628-637. PubMed ID: 29723926 [TBL] [Abstract][Full Text] [Related]
9. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries. Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205 [TBL] [Abstract][Full Text] [Related]
10. Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly. Rangganata E; Widia F; Rahardjo HE Acta Med Indones; 2020 Jul; 52(3):255-263. PubMed ID: 33020336 [TBL] [Abstract][Full Text] [Related]
11. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. Wagg A; Compion G; Fahey A; Siddiqui E BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769 [TBL] [Abstract][Full Text] [Related]
12. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072 [TBL] [Abstract][Full Text] [Related]
13. Antimuscarinic use and discontinuation in an older adult population. Vouri SM; Schootman M; Strope SA; Xian H; Olsen MA Arch Gerontol Geriatr; 2019; 80():1-11. PubMed ID: 30268971 [TBL] [Abstract][Full Text] [Related]
14. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Wagg A; Nitti VW; Kelleher C; Castro-Diaz D; Siddiqui E; Berner T Curr Med Res Opin; 2016; 32(4):621-38. PubMed ID: 26828974 [TBL] [Abstract][Full Text] [Related]
15. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial. Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. Andersson KE; Sarawate C; Kahler KH; Stanley EL; Kulkarni AS BJU Int; 2010 Jul; 106(2):268-74. PubMed ID: 19922546 [TBL] [Abstract][Full Text] [Related]
18. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423 [TBL] [Abstract][Full Text] [Related]
19. No Increased Risk of Fracture in Patients Receiving Antimuscarinics for Overactive Bladder Syndrome: A Retrospective Cohort Study. Kao LT; Huang CY; Lin HC; Chu CM J Clin Pharmacol; 2018 Jun; 58(6):727-732. PubMed ID: 29315618 [TBL] [Abstract][Full Text] [Related]
20. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. Kessler TM; Bachmann LM; Minder C; Löhrer D; Umbehr M; Schünemann HJ; Kessels AG PLoS One; 2011 Feb; 6(2):e16718. PubMed ID: 21373193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]